Keon-Joo Lee

Keon-Joo Lee

Auto-generated profile, based on publicly available information

Keon-Joo Lee

Department of Neurology, Korea University College of Medicine, Korea University Guro Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2015 in Epidemiology and Health
Verified
Journal Article
Open access
PDF file
YPYong-Shik Park
Yong-Shik Park
CLChanghwan Lee
Changhwan Lee
KKKyung Min Kim
Kyung Min Kim
SKSeung Woo Kim
Seung Woo Kim
KLKeon-Joo Lee
Keon-Joo Lee
MKMoran Ki
Moran Ki
This study reviewed problems in the prevention of outbreak and spread of Middle East Respiratory Syndrome (MERS) and aimed to provide assistance in establishing policies to prevent and manage future outbreaks of novel infectious diseases of foreign origin via in-depth epidemiological investigation of the patient who initiated the MERS outbreak in Korea, 2015. Personal and phone interviews were conducted with the patient and his guardians, and his activities in Saudi Arabia were investigated with the help of the Saudi Arabian Ministry of Health. Clinical courses and test results were confirmed from the medical records. The patient visited 4 medical facilities and contacted 742 people between May 11, 2015, at symptom onset, and May 20, at admission to the National Medical Center; 28 people were infected and diagnosed with MERS thereafter. Valuable lessons learned included: (1) epidemiological knowledge on the MERS transmission pattern and medical knowledge on its clinical course; (2) improvement of epidemiological investigative methods via closed-circuit television, global positioning system tracking, and review of Health Insurance Review and Assessment Service records; (3) problems revealed in the existing preventive techniques, including early determination of the various people contacted; (4) experiences with preventive methods used for the first time in Korea, including cohort quarantine; (5) reconsideration of the management systems for infectious disease outbreaks across the country, such as this case, at the levels of central government, local government, and the public; (6) reconsideration of hospital infectious disease management systems, culture involving patient visitation, and emergency room environments.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JKJihoon Kang
Jihoon Kang
SKSeong-Eun Kim
Seong-Eun Kim
HPHong-Kyun Park
Hong-Kyun Park
YCYong-Jin Cho
Yong-Jin Cho
JKJun Yup Kim
Jun Yup Kim
HBHee-Joon Bae
Hee-Joon Bae
Kang J, et al. J Korean Med Sci. 2020 Sep;35(41):e347. https://doi.org/10.3346/jkms.2020.35.e347

1 December 2019 in European Stroke Journal
Verified
Journal Article
Open access
PDF file
HPHong-Kyun Park
Hong-Kyun Park
SKSeong-Eun Kim
Seong-Eun Kim
YCYong-Jin Cho
Yong-Jin Cho
JKJun Yup Kim
Jun Yup Kim
HOHyunji Oh
Hyunji Oh
HBHee-Joon Bae
Hee-Joon Bae
There is limited information about non-selective and contemporary data on quality of stroke care and its variation among hospitals at a national level. We analysed data of the patients admitted to 258 acute stroke care hospitals covering the entire country from the Acute Stroke Quality Assessment Program, which was performed by the Health Insurance Review and Assessment Service from 2008 to 2014 in South Korea. The primary outcome measure was defect-free stroke care (all-or-none), based on six get with the guidelines-stroke performance measures (except venous thromboembolism prophylaxis). Among 43,793 acute stroke patients (mean age, 67 ± 14 years; male, 55%), 31,915 (72.9%) were hospitalised due to ischaemic stroke. At a patient level, defect-free stroke care steadily increased throughout the study period (2008, 80.2% vs. 2014, 92.1%), but there were large disparities among hospitals (mean = 50.7%, SD = 21.7%). Defect-free stroke care was given more frequently in patients being treated in hospitals with 25 or more stroke cases per month (odds ratio [OR] 2.83; 95% confidence interval [CI] 1.69–4.72), delivery of intravenous thrombolysis one or more times per month (OR 2.37; 95% CI 1.44–3.92), or provision of stroke unit care (OR 1.75; 95% CI 1.22–2.52). This study shows that the quality of stroke care in Korea is improving over time and is higher in centres with a larger volume of stroke or intravenous thrombolysis cases and providing stroke unit care but hospital disparities exist. Reducing large differences in defect-free stroke care among acute stroke care hospitals should be continuously pursued.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JKJun Yup Kim
Jun Yup Kim
KLKeon-Joo Lee
Keon-Joo Lee
JKJihoon Kang
Jihoon Kang
Beomjoon KimBeomjoon Kim
Beomjoon Kim
SKSeong-Eun Kim
Seong-Eun Kim
HBHee-Joon Bae
Hee-Joon Bae
Kim JY, et al. J Korean Med Sci. 2020 Apr;35(20):e167. https://doi.org/10.3346/jkms.2020.35.e167

21 June 2019 in International Journal of Stroke
Verified
Journal Article
Open access
PDF file
XWXia Wang
Xia Wang
JLJingwei Li
Jingwei Li
TMTom J Moullaali
Tom J Moullaali
KLKeon-Joo Lee
Keon-Joo Lee
Beomjoon KimBeomjoon Kim
Beomjoon Kim
Vijay sharmaVijay sharma
Vijay sharma
Objective: To investigate the comparative efficacy and safety of the low-dose versus standard-dose alteplase using real-world acute stroke registry data from Asian countries. Methods: Individual participant data were obtained from nine acute stroke registries from China, Japan, Philippines, Singapore, South Korea, and Taiwan between 2005 and 2018. Inverse probability of treatment weight was used to remove baseline imbalances between those receiving low-dose versus standard-dose alteplase. The primary outcome was death or disability defined by modified Rankin Scale scores of 2 to 6 at 90 days. Secondary outcomes were symptomatic intracerebral hemorrhage and death. Generalized linear mixed models with the individual registry as a random intercept were performed to determine associations of treatment with low-dose alteplase and outcomes. Results: Of the 6250 patients (mean age 66 years, 36% women) included in these analyses, 1610 (24%) were treated with low-dose intravenous alteplase. Clinical outcomes for low-dose alteplase were not significantly different to those for standard-dose alteplase, adjusted odds ratios for death or disability: 1.00 (0.85–1.19) and symptomatic intracerebral hemorrhage 0.87 (0.63–1.19), except for lower death with borderline significance, 0.77 (0.59–1.01). Conclusions: The present analyses of real-world Asian acute stroke registry data suggest that low-dose intravenous alteplase has overall comparable efficacy for functional recovery and greater potential safety in terms of reduced mortality, to standard-dose alteplase for the treatment of acute ischemic stroke.

1 February 2026 in Stroke
Verified
Journal Article
Closed access
HKHyunsoo Kim
Hyunsoo Kim
JKJoon-Tae Kim
Joon-Tae Kim
JLJi Sung Lee
Ji Sung Lee
Beomjoon KimBeomjoon Kim
Beomjoon Kim
JKJihoon Kang
Jihoon Kang
HBHee-Joon Bae
Hee-Joon Bae
BACKGROUND: Early neurological deterioration (END) is a frequent complication of acute ischemic stroke. Although END worsens clinical outcomes, standardized treatment strategies remain undefined, resulting in variability in clinical practice. This study examines real-world treatment patterns for END and compares the effects of different strategies on neurological and functional outcomes. METHODS: This study analyzed data from a nationwide, prospective, multicenter stroke registry in South Korea, including patients with noncardioembolic stroke who developed END due to stroke progression between January 2019 and August 2024. END was defined as new or worsening neurological symptoms meeting National Institutes of Health Stroke Scale criteria (≥2-point total or ≥1 point in consciousness or motor subscores) with radiological confirmation. Patients were classified into conservative management, antithrombotics change, and induced hypertension (iHTN). The primary outcomes were neurological improvement, defined as a ≥2-point reduction in the National Institutes of Health Stroke Scale score, and 3-month functional outcome measured by modified Rankin Scale ordinal shift. Secondary outcomes included good functional recovery (modified Rankin Scale score, 0–2) and composite vascular events (death, stroke, and myocardial infarction). Multivariable analyses adjusted for age, sex, prestroke modified Rankin Scale, initial National Institutes of Health Stroke Scale score, vascular risk factors, the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification, acute thrombolysis, and laboratory covariates. RESULTS: Among 3067 patients with END due to stroke progression, 1840 (60.0%) received conservative management, 747 (24.4%) underwent antithrombotic changes, and 480 (15.7%) were treated with iHTN. Neurological improvement occurred in 34.2% of patients, with the highest in the iHTN group (41.5%) compared with the conservative (32.2%) and antithrombotics change groups (34.4%; P <0.001). In adjusted analyses, iHTN increased the odds of neurological improvement (adjusted odds ratio, 1.55 [95% CI, 1.25–1.92]) and a favorable 3-month modified Rankin Scale shift (adjusted odds ratio, 1.24 95% CI, 1.03–1.48]) compared with conservative management, particularly in patients with large artery atherosclerosis. Antithrombotics change showed no significant association with neurological or functional recovery. CONCLUSIONS: In patients with noncardioembolic ischemic stroke who developed END due to stroke progression, iHTN was associated with favorable clinical outcomes.